Given the clear need for better treatment options for depression, as up to 50% of patients do not respond to current antidepressants, we believe additional studies of the role of MeCP2 in depression are necessary and may open new opportunities for the development of novel antidepressants. This evidence concerns the gene MECP2 and major depressive disorder.